In addition to the two mRNA vaccines Comirnaty and Spikevax, the vector-based vaccine from Janssen has also recently been used in Switzerland (though in a limited number of persons). The side effects profile of this vaccine differs from that of the mRNA vaccines in certain respects. However, it is important to have information about any specific, very rare side effects of this vaccine, such as thrombocytopenia thrombosis syndrome, capillary leak syndrome or Guillain-Barré syndrome, so that appropriate diagnostic and therapeutic measures can be taken in good time in such cases. For details regarding this vaccine, please consult the current Swiss Information for healthcare professionals.
Medical professionals are requested to report any serious and previously unknown side effects to Swissmedic. In doing so, they can actively help to improve knowledge of the safety profile of a medicinal product or vaccine. To submit reports, please use our electronic reporting portal ElViS.